Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2022-03-10 00:00:00 ET · period of report 2022-03-08 · accession 0001567619-22-006720 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-10 | 2022-03-08 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $0.00 | +34.8K | 338.6K | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-08 | A | A | 34,780 | $0.00 | 338,569 | D | — | — | (F1) Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. (F2) Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return for 2019 through 2021 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. (F3) Although earned, the RSUs only vest according to the following schedule: 100% vests on March 15, 2022, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. |